BioInvent International AB · OMXSTO:BINV
BioInvent International AB — Investor Presentation (July 2022)
23 slides from BioInvent International AB's investor presentation, July 2022
Slide 1: July 2022
ee July 2022 e e e Biolnvent
Slide 2: Forward-Looking Statement
FORWARD-LOOKING STATEMENT This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in BioInvent International AB (“BioInvent”). Neither shall the presentation or any
Slide 3: BioInvent is translating cancer biology into innovative immuno-oncology therapies
BIOINVENT IS TRANSLATING CANCER BIOLOGY INTO INNOVATIVE IMMUNO-ONCOLOGY THERAPIES Integrated research engine, functional screening and GMP manufacturing Four expanding clinical programs, a fifth expected to start in July Technology validating deals with Exelixis, Pfizer, Daiichi Sankyo, Bayer Health
Slide 4: Function F.I.R.S.T discovery of new oncology targets and antibodies
FUNCTION F.I.R.S.T™ DISCOVERY OF NEW ONCOLOGY TARGETS AND ANTIBODIES 4 │
Slide 5: Strong pipeline with multiple value drivers
STRONG PIPELINE WITH MULTIPLE VALUE DRIVERS 5 │
Slide 6: BI-1206 in non-Hodgkin's lymphoma: value proposition, key segments and value drivers
BI-1206 IN NON-HODGKIN’S LYMPHOMA: VALUE PROPOSITION – KEY SEGMENTS & VALUE DRIVERS KEY SUB-SEGMENTS OF NON-HODGKIN’S LYMPHOMA (NHL) BI-1206 value drivers • Compelling scientific rationale in anti-CD20 refractory B-cell lymphoma • Chemo-free regimen • Favorable safety profile MZL MZL USD MCL MCL • S
Slide 7: BI-1206 to advance into expansion stage after End-of-Phase 1 FDA meeting
’Biolnvent Biolnvent’s Bl-1206 to advance into expansion stage of Phase 1/2a study in NHL after a productive End-of-Phase 1 FDA meeting © BI-1205 moving into expansion phase as planned « Data presented so far include early signs of efficacy ‘+ Next steps to include planning potentially pivotal Phase
Slide 8: BI-1206 in combination with rituximab: open label Phase 1/2a study
BI-1206 IN COMBINATION WITH RITUXIMAB: Ongoing phase OPEN LABEL PHASE 1/2a STUDY STUDY OVERVIEW Part A Part B BI-1206 + RTX1 BI-1206 + RTX1 3+3 dose escalation Expansion phase 2a Patients with: (n=9-12) PHASE 1 (n=12) relapsed or refractory iNHL 4 weekly doses followed STATUS 4 weekly doses followed
Slide 9: BI-1206 ongoing Phase 1/2a: impressive response rates in follicular lymphoma
BI-1206 ONGOING PHASE 1/2a: IMPRESSIVE RESPONSE RATES IN FOLLICULAR LYMPHOMA RESPONSES FROM SEVEN OF NINE PATIENTS FL SUBGROUP ANALYSIS AS OF Q4 2021 WITH FOLLICULAR LYMPHOMA • Overall response rate 67%, Disease control rate 78% 12 • 9 Follicular Lymphoma (FL) patients evaluated for response 10 – 3
Slide 10: BI-1206 (NHL): key milestones 2022
BI-1206 (NHL): KEY MILESTONES 2022 H1 Select RP2D, and move to expansion phase (Part B) of the study ✓ H1 EoP1 meeting with FDA Discuss RP2D and Phase 2 study design ✓ H2 Include China in global clinical development strategy: implement Part B H2 Start evaluation of subcutaneous formulation of BI-120
Slide 11: BI-1206 in combination with pembrolizumab (solid tumors): Phase 1/2a study with Merck
BI-1206 IN COMBINATION WITH PEMBROLIZUMAB (SOLID TUMORS): Ongoing phase PHASE 1/2a STUDY WITH MERCK STUDY OVERVIEW Part A Part B “If successful, the potential addressable Patients with: BI-1206 + pembrolizumab EARLY BI-1206 + pembrolizumab market could be solid tumors relapsed (200mg) PHASE 1 (200mg
Slide 12: BI-1206: substantial indication growth potential
Autoimmune diseases BI-1206: SUBSTANTIAL INDICATION Other solid tumors GROWTH POTENTIAL NSCLC ESTABLISHING PROOF OF CONCEPT IN CERTAIN INDICATIONS CAN LEAD Metastatic TO RAPID GROWTH IN TOTAL melanoma ADDRESSABLE MARKET NHL iNHL 12 │
Slide 13: BI-1808: a first-in-class anti-TNFR2 antibody
BI-1808: A FIRST-IN-CLASS anti-TNFR2 ANTIBODY TNFR2 shown to be important for tumor expansion and survival, representing a new and promising target for cancer immunotherapy 13 │
Slide 14: BI-1808 (anti-TNFR2): Phase 1 ongoing clinical study design
BI-1808 (ANTI-TNFR2): PHASE 1 ONGOING Ongoing phase CLINICAL STUDY DESIGN Phase 1: All Cancer Types Phase 2a: Tissue-specific cohorts - 12 patients each DOSE ESCALATION – PART A BI-1808 at RP2D - Single agent BI-1808 administered at ascending doses – Single agent BI-1808 single agent Recommended Pha
Slide 15: AACR data boost prospects for BI-1808
AACR data boost prospects for BI-1808 Similar biomarker correlations in patients as preclinically • Very good tolerability profile in tox studies and no safety concerns in the clinical trial to date. • Clear relationship between dose, receptor occupancy (RO) and efficacy in vivo. Soluble TNFR2 clear
Slide 16: BT-001: Phase 1/2a ongoing, partnership with Transgene
BT-001: PHASE 1/2a ONGOING 50/50 partnership with Transgene to develop next generation oncolytic viruses mAbs and oncolytic virus attack the solid tumor together Oncolytic virus & anti-CTLA-4 antibody combination elicits stronger antitumor response & targeted expression of anti-CTLA-4 antibody to im
Slide 17: BT-001 ongoing Phase 1/2a open-label multicenter dose-escalation study
BT-001 (VVcopTK-RR-,ANTI-CTLA-4, GM-CSF): ONGOING PHASE 1/2a OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY PHASE 1 - PART A & B PHASE 2a SEVERAL COHORTS, DIFFERENT TUMOR TYPES UP TO 42 PATIENTS UP TO 12 PATIENTS PART B: BT-001 intratumoral administration BT-001 intratumorally in PART A: in combinat
Slide 18: External pipeline in development by our licensees
EXTERNAL PIPELINE IN DEVELOPMENT BY OUR LICENSEES • Exclusive Option and License agreement signed with Exelixis in June 2022 - Target and antibody discovery performed using BioInvent’s proprietary n-CoDeR® antibody library and patient-centric F.I.R.S.T™ screening platform - 25 MUSD upfront payment -
Slide 19: Upcoming near-term key catalysts
UPCOMING NEAR-TERM KEY CATALYSTS BI-1206 FIRST PATIENT ENROLLED IN CHINA – MID-2022E START EVALUATION OF SUBCUTANEOUS FORMULATION – H2 2022E BI-1808 INITIAL SINGLE-AGENT PHASE 1 CLINICAL DATA – MID-2022 BT-001 START OF PHASE 1 PART B (COMBINATION WITH PEMBRO) – H2 2022E BI-1607 START OF CLINICAL PHA
Slide 20: www.bioinvent.com
www.bioinvent.com Follow us on LinkedIn & Twitter
Slide 21: Appendix
<a APPENDIX *Y Biolnvent
Slide 22: BI-1206 in combination with rituximab
BI-1206 IN COMBINATION WITH RITUXIMAB 22 │
Slide 23: BI-1206 in combination with pembrolizumab
BI-1206 IN COMBINATION WITH PEMBROLIZUMAB 23 │
BioInvent International — Investor Presentation (July 2022) on 6ix